Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

A Comprehensive Genetic Analysis of MDS Patients From Peripheral Blood Combining FISH- and SNP-Array-Analysis

Christina Ganster, Katayoon Shirneshan, Gabriela Salinas-Riester, Friederike Braulke, Julie Schanz, Katharina S. Götze, Gesine Bug, Peter Majunke, Aristoteles Giagounidis, Catharina Müller-Thomas, Andrea Kündgen, Ulrich Germing, Lorenz Trümper, Uwe Platzbecker, MD, Detlef Haase

Blood (2012) 120 (21): 4926.

https://doi.org/10.1182/blood.V120.21.4926.4926

Published: 2012

Journal Articles

First Interim Efficacy and Safety Analysis of an International Phase III Randomized Trial in Newly Diagnosed Systemic Peripheral T-Cell Lymphoma Treated with Chemotherapy with or without Alemtuzumab and Consolidated by High Dose Therapy

Blood (2012) 120 (21): 57.

https://doi.org/10.1182/blood.V120.21.57.57

Published: 2012

Journal Articles

CD34+ FISH As a New Method for Molecular-Cytogenetic Diagnostic From Peripheral Blood in MDS: Update of the Multicenter German Prospective Diagnostic Study

Blood (2012) 120 (21): 3816.

https://doi.org/10.1182/blood.V120.21.3816.3816

Published: 2012

Journal Articles

SOCS1 Mutation Subtypes Predict Divergent Outcomes in DLBCL Patients

Jochen K Lennerz, MD, PhD, Birgit Schif, Christian W Kohler, PhD, Stefan Bentink, PhD, Markus Kreuz, Ingo Melzner, PhD, Lorenz Trümper, Markus Löffler, MD, Rainer Spang, Peter Moeller, MD

Blood (2012) 120 (21): 419.

https://doi.org/10.1182/blood.V120.21.419.419

Published: 2012

Journal Articles

First Interim Safety Analysis of a Phase III Randomized Trial in Newly Diagnosed Systemic Peripheral T-Cell Lymphoma Treated with CHOP Chemotherapy with or without Alemtuzumab and Consolidated by Autologous Hematopoietic Stem Cell Transplant,

Blood (2011) 118 (21): 4110.

https://doi.org/10.1182/blood.V118.21.4110.4110

Published: 2011

Journal Articles

Detection of Karyotype Evolution From Peripheral Blood by Sequential FISH Analyses of Circulating CD34+ Cells In MDS Patients: Results of the Ongoing German Multicenter Prospective Diagnostic Study

Friederike Braulke, MD, Julie Schanz, MD, Michael Metz, MD, Sven Detken, MD, Joerg Seraphin, MD, Katharina Götze, MD, Catharina Mueller-Thomas, MD, Uwe Platzbecker, MD, Tim Henrik Brümmendorf, MD, Aristoteles A.N. Giagounidis, MD, Ulrich Germing, MD, Kathleen Jentsch-Ullrich, MD, Angelika Boehme, MD, Gesine Bug, MD, Oliver G. Ottmann, Prof, Dr., med., Philippe Schafhausen, MD, Lorenz Trümper, MD, Detlef Haase, MD

Blood (2010) 116 (21): 2937.

https://doi.org/10.1182/blood.V116.21.2937.2937

Published: 2010

Journal Articles

Randomised Intergroup Trial of First line Treatment for young Low-Risk Patients (<61 years) with Diffuse Large B-Cell Non-Hodgkin's Lymphoma (DLBCL) with a CHOP-like Regimen with or without the Anti-CD20 Antibody Rituximab – 6-Year Follow-up of the Mint Study of the Mabthera International Trial (MInT) Group

Blood (2010) 116 (21): 111.

https://doi.org/10.1182/blood.V116.21.111.111

Published: 2010

Journal Articles

CNS Disease In Younger Patients (<=60 years) with Aggressive Lymphoma Treated In Trials of the German High Grade Non Hodgkin Lymphoma Study Group (DSHNHL) and the MabThera International Trial (MInT)

Norbert Schmitz, MD, Samira Zeynalova, Bertram Glass, MD, Ulrich Kaiser, MD, Eva Cavallin-Stahl, MD, Max Wolf, MBBS, FRACP, FRCPA, Mathias Haenel, MD, Markus Loeffler, MD, Lorenz Trümper, MD, M. Pfreundschuh

Blood (2010) 116 (21): 112.

https://doi.org/10.1182/blood.V116.21.112.112

Published: 2010

Journal Articles

Significant Suppression of the Colony Forming Capacity of Erythroid Progenitors by Iron Overload in Patients with MDS and Sequential Anlyses of BFU-E Under Chelation Therapy.

Julia Hartmann, Ursula Sinzig, Gerald Wulf, MD, Lorenz Trümper, Frank Konietschke, Stephanie Fischer, Detlef Haase, MD, PhD

Blood (2009) 114 (22): 3826.

https://doi.org/10.1182/blood.V114.22.3826.3826

Published: 2009

Journal Articles

Aggressive Chemotherapy (CHOEP-14) and Rituximab or High-Dose Therapy (MegaCHOEP) and Rituximab for Young, High-Risk Patients with Aggressive B-Cell Lymphoma: Results of the MegaCHOEP Trial of the German High — Grade Non-Hodgkin Lymphoma Study Group (DSHNHL).

Norbert Schmitz, Maike Nickelsen, Marita Ziepert, Matthias Haenel, Peter Borchmann, PD, Dr., Andreas Viardot, Christina Nickenig, Martin Bentz, MD, Christian Peschel, MD, Lorenz Trümper, Markus Loeffler, Michael Pfreundschuh, Bertram Glass, MD, PhD

Blood (2009) 114 (22): 404.

https://doi.org/10.1182/blood.V114.22.404.404

Published: 2009

Journal Articles

Early Autologous Stem Cell Transplantation (autoSCT) May Overcome the Adverse Impact of Del 11q- in Poor-Risk Chronic Lymphocytic Leukemia (CLL): Results From the GCLLSG CLL3 Trial.

Peter Dreger, Hartmut Döhner, Hildegard Greinix, MD, Fabienne McClanahan, MD, Manfred Hensel, Bernd Hertenstein, Ulrich Dührsen, MD, PhD, Markus Hentrich, Lorenz Trümper, Ruth Sonnen, Bertold Emmerich, Wolfgang Ulrich Knauf, Georg Hopfinger, MD, Michael Hallek, Michael Kneba, MD, PhD, Norbert Schmitz, Stephan Stilgenbauer, MD

Blood (2009) 114 (22): 879.

https://doi.org/10.1182/blood.V114.22.879.879

Published: 2009

Journal Articles

Autologous Stem Cell Transplantation and Addition of Rituximab Independently Prolong Response Duration in Advanced Stage Mantle Cell Lymphoma.

Eva Hoster, Bernd Metzner, Roswitha Forstpointner, Michael Pfreundschuh, Lorenz Trümper, Michael Hallek, Bernhard Wörmann, Ulrich Dührsen, MD, Christian Gisselbrecht, Hanneke C. Kluin-Nelemans, Achiel Van Hoof, Michael Unterhalt, Wolfgang Hiddemann, Martin H. Dreyling

Blood (2009) 114 (22): 880.

https://doi.org/10.1182/blood.V114.22.880.880

Published: 2009

Journal Articles

The Glycogensynthase Kinase 3b (GSK-3β) Is Involved in Leukemic Transformation

Jörg Bäsecke, Anneke Lehmann, Ulla Bergholz, James McCubrey, PhD, Lorenz Trümper, Carol Stocking, Stefan Horn

Blood (2008) 112 (11): 4489.

https://doi.org/10.1182/blood.V112.11.4489.4489

Published: 2008

Journal Articles

Subcutaneous Alemtuzumab (MabCampath) in Fludarabine-Refractory CLL (CLL2H Trial of the GCLLSG).

Stephan Stilgenbauer, Dirk Winkler, Andreas Bühler, Thorsten Zenz, Silja Groner, Raymonde Busch, Manfred Hensel, Ulrich Dührsen, Jürgen Finke, Peter Dreger, Ulrich Jäger, Eva Lengfelder, Lorenz Trümper, Ulrike Söling, Rudolf Schlag, Michael Hallek, Hartmut Döhner

Blood (2007) 110 (11): 3120.

https://doi.org/10.1182/blood.V110.11.3120.3120

Published: 2007

Journal Articles

Dose-escalated CHOP plus etoposide (MegaCHOEP) followed by repeated stem cell transplantation for primary treatment of aggressive high-risk non-Hodgkin lymphoma

Bertram Glass, Marita Kloess, Martin Bentz, Günter Schlimok, Wolfgang E. Berdel, Alfred Feller, Lorenz Trümper, Markus Loeffler, Michael Pfreundschuh, Norbert Schmitz, for the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL)

Blood (2006) 107 (8): 3058–3064.

https://doi.org/10.1182/blood-2005-04-1570

Published: 2006

Journal Articles

Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group

Blood (2005) 106 (12): 3725–3732.

https://doi.org/10.1182/blood-2005-01-0016

Published: 2005

Journal Articles

Subcutaneous Campath-1H (Alemtuzumab) in Fludarabine-Refractory Cll: Interim Analysis of the CLL2h Study of the German Cll Study Group (GCLLSG).

Stephan Stilgenbauer, MD, Dirk Winkler, MD, Alexander Kröber, MD, Dirk Kienle, MD, Michael Hallek, MD, Manfred Hensel, MD, Eva Lengfelder, MD, Lorenz Trümper, MD, Peter Dreger, MD, Ulrich Jäger, MD, Hartmut Döhner, MD, the GCLLSG

Blood (2004) 104 (11): 478.

https://doi.org/10.1182/blood.V104.11.478.478

Published: 2004

Journal Articles

Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL

Michael Pfreundschuh, Lorenz Trümper, Marita Kloess, Rudolf Schmits, Alfred C. Feller, Christian Rudolph, Marcel Reiser, Dieter K. Hossfeld, Bernd Metzner, Dirk Hasenclever, Norbert Schmitz, Bertram Glass, Christian Rübe, Markus Loeffler, the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL)

Blood (2004) 104 (3): 626–633.

https://doi.org/10.1182/blood-2003-06-2094

Published: 2004

Journal Articles

Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL

Michael Pfreundschuh, Lorenz Trümper, Marita Kloess, Rudolf Schmits, Alfred C. Feller, Christian Rübe, Christian Rudolph, Marcel Reiser, Dieter K. Hossfeld, Hartmut Eimermacher, Dirk Hasenclever, Norbert Schmitz, Markus Loeffler, the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL)

Blood (2004) 104 (3): 634–641.

https://doi.org/10.1182/blood-2003-06-2095

Published: 2004

Journal Articles

Classical Hodgkin lymphoma is characterized by recurrent copy number gains of the short arm of chromosome 2

Stefan Joos, Christiane K. Menz, Gunnar Wrobel, Reiner Siebert, Stefan Gesk, Sibylle Ohl, Gunhild Mechtersheimer, Lorenz Trümper, Peter Möller, Peter Lichter, Thomas F. E. Barth

Blood (2002) 99 (4): 1381–1387.

https://doi.org/10.1182/blood.V99.4.1381

Published: 2002

NARROW

A Comprehensive Genetic Analysis of MDS Patients From Peripheral Blood Combining FISH- and SNP-Array-Analysis

First Interim Efficacy and Safety Analysis of an International Phase III Randomized Trial in Newly Diagnosed Systemic Peripheral T-Cell Lymphoma Treated with Chemotherapy with or without Alemtuzumab and Consolidated by High Dose Therapy

CD34+ FISH As a New Method for Molecular-Cytogenetic Diagnostic From Peripheral Blood in MDS: Update of the Multicenter German Prospective Diagnostic Study

SOCS1 Mutation Subtypes Predict Divergent Outcomes in DLBCL Patients

First Interim Safety Analysis of a Phase III Randomized Trial in Newly Diagnosed Systemic Peripheral T-Cell Lymphoma Treated with CHOP Chemotherapy with or without Alemtuzumab and Consolidated by Autologous Hematopoietic Stem Cell Transplant,

Detection of Karyotype Evolution From Peripheral Blood by Sequential FISH Analyses of Circulating CD34+ Cells In MDS Patients: Results of the Ongoing German Multicenter Prospective Diagnostic Study

CNS Disease In Younger Patients (<=60 years) with Aggressive Lymphoma Treated In Trials of the German High Grade Non Hodgkin Lymphoma Study Group (DSHNHL) and the MabThera International Trial (MInT)

Significant Suppression of the Colony Forming Capacity of Erythroid Progenitors by Iron Overload in Patients with MDS and Sequential Anlyses of BFU-E Under Chelation Therapy.

Aggressive Chemotherapy (CHOEP-14) and Rituximab or High-Dose Therapy (MegaCHOEP) and Rituximab for Young, High-Risk Patients with Aggressive B-Cell Lymphoma: Results of the MegaCHOEP Trial of the German High — Grade Non-Hodgkin Lymphoma Study Group (DSHNHL).

Early Autologous Stem Cell Transplantation (autoSCT) May Overcome the Adverse Impact of Del 11q- in Poor-Risk Chronic Lymphocytic Leukemia (CLL): Results From the GCLLSG CLL3 Trial.

Autologous Stem Cell Transplantation and Addition of Rituximab Independently Prolong Response Duration in Advanced Stage Mantle Cell Lymphoma.

The Glycogensynthase Kinase 3b (GSK-3β) Is Involved in Leukemic Transformation

Subcutaneous Alemtuzumab (MabCampath) in Fludarabine-Refractory CLL (CLL2H Trial of the GCLLSG).

Dose-escalated CHOP plus etoposide (MegaCHOEP) followed by repeated stem cell transplantation for primary treatment of aggressive high-risk non-Hodgkin lymphoma

Subcutaneous Campath-1H (Alemtuzumab) in Fludarabine-Refractory Cll: Interim Analysis of the CLL2h Study of the German Cll Study Group (GCLLSG).

Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL

Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL

Classical Hodgkin lymphoma is characterized by recurrent copy number gains of the short arm of chromosome 2

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only